- 1.
Gaucher PC. De l`epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie. Doktoravhandling. Paris: 1882.
- 2.
Epstein E. Beitrag zur chemie der Gaucherschen krankheit. Biochem Z 1924; 145: 398 – 414.
- 3.
Groen JF. The hereditary mechanism of Gauchers disease. Blood 1948; 3: 1238 – 49.
- 4.
Brady RO, Kanjer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gauchers disease. Biochem Biophys Res Commun 1965; 18: 221 – 5.
- 5.
Incerti C. Gauchers disease: an overview. Semin Hematol 1995; 32 (suppl 1): 3 – 9.
- 6.
Clarke JTR. Gauchers disease: differential diagnosis. Mol Med Ther 1997; 5: 6 – 12.
- 7.
Erikson A, Karlberg J, Skogman AL,Dreborg S. Gaucher disease type 3: intellectual profile. Pediatr Neurol 1987; 3: 87 – 9.
- 8.
Esplin JA. The diagnosis of Gauchers disease. I: The hematologic impact of Gaucher`s disease: proceedings of a symposium, December 4, 1992, Anaheim, California, USA. Pawling, New York: Cadeceus Medical, 1993: 8 – 9.
- 9.
Pastores GM, Einhorn TA. Skeletal complications of Gaucher`s disease: pathophysiology, evaluation and treatment. Semin Hematol 1995; 32 (suppl 1): 20 – 7.
- 10.
Hermann G, Pastores GM, Abdelwahab IF, Lorberboym AM. Gaucher`s disease: assessment of skeletal involvement and therapeutic responses to enzyme treatment. Skeletal Radiol 1997; 26: 687 – 96.
- 11.
Barranger JA, Rice EO. Gauchers disease: diagnosis, monitoring, and management. Mol Med Ther 1997; 5: 1 – 6.
- 12.
Bohm P, Kunz W, Horny HP, Einsele H. Adult Gaucher disease in association with primary malignant bone tumors. Cancer 2001; 91: 457 – 62.
- 13.
Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher`s disease. Lancet 2001; 358: 324 – 7.
- 14.
Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, Horowitz M, Abrahamov A, Zimran A. Gynecologic and obstetric aspects of Gaucher`s disease: a survey of 53 patients. Am J Obstet Gynecol 1995; 172: 1284 – 90.
- 15.
Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160: 2835 – 43.
- 16.
Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 2000; 15: 181 – 8.
- 17.
Abrahamov A, Elstein D, Gross-Tsur V, Farber B, Glaser Y, Hadas-Halpern I et al. Gaucher`s disease variant characterized by progressive calcification of heart valves and unique phenotype. Lancet 1995; 346: 1000 – 3.
- 18.
Hollak CEM, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 2001; 24 (suppl 2): 97 – 105.
- 19.
Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity. J Clin Invest 1994; 93: 1288 – 92.
- 20.
Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 1998; 12: 115 – 33.
- 21.
Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33 – 9.
- 22.
Barranger JA, O`Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 2001; 24 (suppl 2): 89 – 96.
- 23.
Damiano AM, Pastores GM, Ware JE jr. The health-related quality of life of adults with Gaucher`s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998; 7: 373 – 86.
- 24.
Elstein D, Abrahamov A, Hadas- Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher`s disease. Br J Haematol 2000; 110: 488 – 92.
- 25.
vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001; 113: 1084 – 6.
- 26.
Weinreb NJ. Interruption in enzyme replacement therapy for Gaucher disease. Br J Haematol 2001; 113: 1087 – 8.
- 27.
Neudorf SML. Bone marrow transplantation for the correction of Gaucher disease. Mol Med Ther 1997; 5: 10 – 6.
- 28.
Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001; 24: 275 – 90.
- 29.
Ohashi T, Boggs S, Robbins P, Bahnson A, Patrene K, Wei FS et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 1992; 9: 11332 – 6.
- 30.
Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 1999; 8: 263 – 8.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.